Anne M Neilan1,2,3,4, Alexander J B Bulteel2, Sybil G Hosek5, Julia H A Foote2, Kenneth A Freedberg2,3,4,6,7, Raphael J Landovitz8, Rochelle P Walensky2,3,4,6, Stephen C Resch7, Pooyan Kazemian2,4,6, A David Paltiel9, Milton C Weinstein7, Craig M Wilson10, Andrea L Ciaranello2,3,4. 1. Division of General Academic Pediatrics, Department of Pediatrics, Massachusetts General Hospital, Boston, Massachusetts, USA. 2. Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts, USA. 3. Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA. 4. Harvard Medical School, Boston, Massachusetts, USA. 5. Stroger Hospital of Cook County, Chicago, Illinois, USA. 6. Division of General Internal Medicine, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA. 7. Department of Health Policy and Management, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA. 8. University of California, Los Angeles, California, USA. 9. Yale School of Public Health, New Haven, Connecticut, USA. 10. Department of Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, Alabama, USA.
Abstract
BACKGROUND: Of new HIV infections in the US, 20% occur among young men who have sex with men (YMSM, ages 13-24), but >50% of YMSM with HIV are unaware of their status. Using Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) data, we projected the clinical benefit and cost-effectiveness of frequent HIV screening among high-risk YMSM from age 15. METHODS: Using a mathematical simulation, we examined 3 screening strategies: Yearly, 6-monthly, and 3-monthly, each in addition to the Status quo (SQ, 0.7-10.3% screened/year, stratified by age). We used published data (YMSM-specific when available) including: HIV incidences (0.91-6.41/100PY); screen acceptance (80%), linkage-to-care/antiretroviral therapy (ART) initiation (76%), HIV transmission (0.3-86.1/100PY, by HIV RNA), monthly ART costs ($2290-$3780), and HIV per-screen costs ($38). Projected outcomes included CD4 count at diagnosis, primary HIV transmissions from ages 15-30, quality-adjusted life expectancy, costs, and incremental cost-effectiveness ratios (ICERs, $/quality-adjusted life-year saved [QALY]; threshold ≤$100 000/QALY). RESULTS: Compared to SQ, all strategies increased projected CD4 at diagnosis (296 to 477-515 cells/µL) and quality-adjusted life expectancy from age 15 (44.4 to 48.3-48.7 years) among YMSM acquiring HIV. Compared to SQ, all strategies increased discounted lifetime cost for the entire population ($170 800 to $178 100-$185 000/person). Screening 3-monthly was cost-effective (ICER: $4500/QALY) compared to SQ and reduced primary transmissions through age 30 by 40%. Results were most sensitive to transmission rates; excluding the impact of transmissions, screening Yearly was ≤$100 000/QALY (ICER: $70 900/QALY). CONCLUSIONS: For high-risk YMSM in the US, HIV screening 3-monthly compared to less frequent screening will improve clinical outcomes and be cost-effective.
BACKGROUND: Of new HIV infections in the US, 20% occur among young men who have sex with men (YMSM, ages 13-24), but >50% of YMSM with HIV are unaware of their status. Using Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) data, we projected the clinical benefit and cost-effectiveness of frequent HIV screening among high-risk YMSM from age 15. METHODS: Using a mathematical simulation, we examined 3 screening strategies: Yearly, 6-monthly, and 3-monthly, each in addition to the Status quo (SQ, 0.7-10.3% screened/year, stratified by age). We used published data (YMSM-specific when available) including: HIV incidences (0.91-6.41/100PY); screen acceptance (80%), linkage-to-care/antiretroviral therapy (ART) initiation (76%), HIV transmission (0.3-86.1/100PY, by HIV RNA), monthly ART costs ($2290-$3780), and HIV per-screen costs ($38). Projected outcomes included CD4 count at diagnosis, primary HIV transmissions from ages 15-30, quality-adjusted life expectancy, costs, and incremental cost-effectiveness ratios (ICERs, $/quality-adjusted life-year saved [QALY]; threshold ≤$100 000/QALY). RESULTS: Compared to SQ, all strategies increased projected CD4 at diagnosis (296 to 477-515 cells/µL) and quality-adjusted life expectancy from age 15 (44.4 to 48.3-48.7 years) among YMSM acquiring HIV. Compared to SQ, all strategies increased discounted lifetime cost for the entire population ($170 800 to $178 100-$185 000/person). Screening 3-monthly was cost-effective (ICER: $4500/QALY) compared to SQ and reduced primary transmissions through age 30 by 40%. Results were most sensitive to transmission rates; excluding the impact of transmissions, screening Yearly was ≤$100 000/QALY (ICER: $70 900/QALY). CONCLUSIONS: For high-risk YMSM in the US, HIV screening 3-monthly compared to less frequent screening will improve clinical outcomes and be cost-effective.
Authors: Bruce R Schackman; Ashley A Eggman; Jared A Leff; Megan Braunlin; Uriel R Felsen; Lisa Fitzpatrick; Edward E Telzak; Wafaa El-Sadr; Bernard M Branson Journal: Public Health Rep Date: 2016 Jan-Feb Impact factor: 2.792
Authors: John A Fleishman; Baligh R Yehia; Richard D Moore; P Todd Korthuis; Kelly A Gebo Journal: J Acquir Immune Defic Syndr Date: 2012-07-01 Impact factor: 3.731
Authors: A D Paltiel; J A Scharfstein; G R Seage; E Losina; S J Goldie; M C Weinstein; D E Craven; K A Freedberg Journal: Med Decis Making Date: 1998 Apr-Jun Impact factor: 2.583
Authors: Pedro Cahn; Jan Fourie; Beatriz Grinsztejn; Sally Hodder; Jean-Michel Molina; Kiat Ruxrungtham; Cassy Workman; Tom Van De Casteele; Piet De Doncker; Erkki Lathouwers; Frank Tomaka Journal: AIDS Date: 2011-04-24 Impact factor: 4.177
Authors: Julie Ratcliffe; Elisabeth Huynh; Katherine Stevens; John Brazier; Michael Sawyer; Terry Flynn Journal: Health Econ Date: 2015-02-16 Impact factor: 3.046
Authors: Marie Helleberg; Frederik N Engsig; Gitte Kronborg; Carsten S Larsen; Gitte Pedersen; Court Pedersen; Jan Gerstoft; Niels Obel Journal: AIDS Date: 2012-03-27 Impact factor: 4.177
Authors: Y Yazdanpanah; C Fagard; D Descamps; A M Taburet; C Colin; B Roquebert; C Katlama; G Pialoux; C Jacomet; C Piketty; D Bollens; J M Molina; G Chêne Journal: Clin Infect Dis Date: 2009-11-01 Impact factor: 9.079
Authors: Anne M Neilan; Raphael J Landovitz; Mylinh H Le; Beatriz Grinsztejn; Kenneth A Freedberg; Marybeth McCauley; Nattanicha Wattananimitgul; Myron S Cohen; Andrea L Ciaranello; Meredith E Clement; Krishna P Reddy; Emily P Hyle; A David Paltiel; Rochelle P Walensky Journal: Ann Intern Med Date: 2022-02-01 Impact factor: 51.598
Authors: Anne M Neilan; Audrey C Bangs; Michael Hudgens; Kunjal Patel; Allison L Agwu; Ingrid V Bassett; Aditya H Gaur; Emily P Hyle; Catherine M Crespi; Keith J Horvath; Caitlin M Dugdale; Kimberly A Powers; H Jonathon Rendina; Milton C Weinstein; Rochelle P Walensky; Kenneth A Freedberg; Andrea L Ciaranello Journal: AIDS Behav Date: 2021-02-06